Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Bayer To Report Phase III EINSTEIN-PE Results In Late-BreakingTrials At ACC 2012

Bayer HealthCare, a subgroup of German conglomerate Bayer AG (BYR.L,BAYRY.PK,BAYZF.PK), said that the Phase III EINSTEIN-PE study, with nearly 5,000 patients, would be presented in the Late-Breaking Clinical Trials Session on Monday, March 26th, 2012, 08:00 - 09:30am CDT, at the American College of Cardiology's 61st Annual Scientific Sessions or ACC in Chicago, USA, by lead investigator Harry Buller, MD, Academic Medical Center, Amsterdam, the Netherlands.

The EINSTEIN-PE study compared an oral single-drug approach with rivaroxaban, intensified initial treatment with rivaroxaban 15 mg twice daily for three weeks followed by 20 mg once daily, with the current standard of care of initial subcutaneous enoxaparin followed by a VKA in patients with acute symptomatic pulmonary embolism or PE with or without symptomatic deep vein thrombosis or DVT.

This multinational, randomized, event-driven trial with blinded outcome assessment was sponsored by Bayer HealthCare and Janssen Research & Development, LLC.

Click here to receive FREE breaking news email alerts for Bayer AG and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
LinkedIn Corp., the world's largest online professional network, said Thursday after the markets closed that it swung to a second quarter loss, hurt by higher costs and expenses even as revenue surged 47%. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue. Kraton Performance Polymers, Inc. (KRA), Wednesday reported second-quarter net income of $11.1 million or $0.33 per share, up from $3.8 million or $0.12 per share last year. Adjusted earnings improved to $0.46 per share from $0.15 per share last year. Revenues for the quarter dropped to $323.8... Organic grocer Whole Foods Market, Inc. said Wednesday after the markets closed that its third quarter profit rose 6.3% from last year, as same-store sales increased 3.9%. The company's quarterly earnings per share also came in above analysts' expectations, but its quarterly sales fell shy of analyst' forecast.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.